Are you a senior Pharma executive?

As you know, Pharma is seeing a rapidly diminishing number of mid-stage licensing and acquisition targets, mostly due to the dearth of funding available for these biotechs and the amount of competition in the market. This is forcing pharma to look earlier and earlier as attractive late stage opportunities dry up and cause an increased focus on effective alliance management to drive value from deals. Compounded with a decreasingly efficient internal R&D process, many are wondering where the innovation will come from the drive the future of the pharmaceutical industry.

BioBusiness 2012 tackles this key question and looks to provide the answers with keynotes outlining the future of the industry, case studies addressing what went right (and what didn’t!), panel discussions with industry leading figures, debates on controversial motions and much more whilst breaking down the barrier between speakers and delegates and facilitating open and organic networking at this premier bio-partnering conference. Make sure you don’t miss unique industry insight and benchmark yourself against successful pioneers in the field and meet the biotechs showing true innovation and patient value.

Just a few of the BioBusiness conference speakers you'll meet in 2012:

• Andrew Sandham, Chairman & CEO, Kymab
• Carl Firth, Chief Executive Officer & Founder, ASLAN Pharmaceuticals
• Dan Zabrowski, Global Head of Pharma Partnering, Roche
• David Nicholson, SVP & Head Worldwide Licensing and Knowledge Management, Merck
• Dimitri Dimitriou, Chief Executive Officer, ImmuPharma
• Dirk Reyn, Managing Director, Shire-Movetis
• Edwin Moses, CEO, Ablynx
• George Yeh, President, Taiwan Liposome Company (TLC)
• Herve Lilliu, Vice President Global Health Outcomes, Market Access and Pricing, UCB
• Ian Nicholson, CEO, Chroma Therapeutics
• James Sabry, Vice President, Genentech Partnering, Genentech
• John Adamou, Head, Strategic Transactions & Alliance Management, Boehringer Ingelheim
• Jon Williams, SVP of Strategy, Business Development & Comparative Effectiveness, Medco
• Kevin FitzGerald, CEO, F-star
• Lee Eng Hin, Executive Director, BMRC, A*STAR
• Malcolm Weir, CEO, Heptares Therapeutics
• Melanie Lee, CEO, Syntaxin
• Nicholas Adams, Chief Business Officer, Clavis Pharma
• Onno van de Stolpe, CEO, Galapagos
• Patrik De Haes, CEO, ThromboGenics
• Peter Nolan, Executive Director, SVP Commercial Development, Oxford BioMedica
• Simon Sturge, Corporate Senior Vice President Biopharmaceuticals, Boehringer Ingelheim
• Steven Holtzman, Executive Vice President, Corporate Development, Biogen Idec
• Tehseen Salimi, VP, Global Evidence & Value Development Medical Affairs, Sanofi
• Tim Brears, CEO, Xention
• Werner Lanthaler, CEO, Evotec

6 reasons why you MUST attend:

1. Why the payer’s perspective is paramount to success
   How payer perspectives have become a key part of the innovation process, how they will impact on your success and strategies to take these into account
   • Reverse engineering your drug development to meet changing payer requirements in a new era of reimbursement with panels and case studies from VPs from Medco, UCB and Sanofi
2. Network with key innovative biotechs with promising licensing and acquisition targets
   BioBusiness builds on a reputation for attracting key decision makers from innovative biotech firms
   • Discover case studies outlining innovation and company strategies and benefit from relationships with industry bodies such as One Nucleus and innovative biotechs like Syntaxin, Kymab, f-star, Heptares, Xention, Chroma, Clavis and more.
3. The importance of the emerging markets to future operations
   Harnessing innovation in the emerging markets and bringing this value back into the mature regions
   • Panels addressing promising in-licensing opportunities, experiences and regional approaches with regional expertise from biotechs, pharma and regional government agencies
4. Top-line organisational strategy designed to deliver innovation
   Strategic, forward looking perspectives outlining necessary social organisation, R&D planning, open innovation and academic engagement
   • Determine the most effective way forward, benchmark your strategy against industry leaders and plot the growing importance of academia and open innovation models with Biogen Idec, Merck, Lilly and more
5. Drive value from an effective alliance management strategy
   Making the deal doesn’t create value; it’s what you do after that creates this. Identify the top strategies being employed by industry leaders in order to achieve maximum return from an alliance, how others have re-built their alliance management function organisation-wide and salvaging relationships gone bad
   • Case studies, panels and breakout sessions from Bayer, Biogen Idec, Immupharma and Clavis
6. Analyse the most interesting and innovative deals of 2011
   Deconstruct deal trends and discover the true drivers and outcomes behind the most interesting deals
   • Behind the scenes insight from off-the-record case studies and panels from Astellas, Roche, Genentech, Astrazeneca, Boehringer Ingelheim, Xention, F-Star and more

PLUS: Off-the-record case studies, PowerPoint-free sessions and panels providing insight you won’t receive anywhere else, interactive and challenging breakout sessions giving you the chance to drive the debate and learn from your peers and our renown round-table sessions driven by industry experts.

Previous BioBusiness attendees include: